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Abstract
Alzheimer’s disease is a neurodegenerative disorder typified by the accumulation of a small protein, beta-amyloid, which
aggregates and is the primary component of amyloid plaques. Many new therapeutic and diagnostic agents for reducing
amyloid plaques have limited efficacy in vivo because of poor transport across the blood-brain barrier. Here we demonstrate
that low-intensity focused ultrasound with a microbubble contrast agent may be used to transiently disrupt the blood-brain
barrier, allowing non-invasive, localized delivery of imaging fluorophores and immunotherapeutics directly to amyloid
plaques. We administered intravenous Trypan blue, an amyloid staining red fluorophore, and anti-amyloid antibodies,
concurrently with focused ultrasound therapy in plaque-bearing, transgenic mouse models of Alzheimer’s disease with
amyloid pathology. MRI guidance permitted selective treatment and monitoring of plaque-heavy anatomical regions, such
as the hippocampus. Treated brain regions exhibited 16.565.4-fold increase in Trypan blue fluorescence and 2.761.2-fold
increase in anti-amyloid antibodies that localized to amyloid plaques. Ultrasound-enhanced delivery was consistently
reproduced in two different transgenic strains (APPswe:PSEN1dE9, PDAPP), across a large age range (9–26 months), with
and without MR guidance, and with little or no tissue damage. Ultrasound-mediated, transient blood-brain barrier
disruption allows the delivery of both therapeutic and molecular imaging agents in Alzheimer’s mouse models, which
should aid pre-clinical drug screening and imaging probe development. Furthermore, this technique may be used to deliver
a wide variety of small and large molecules to the brain for imaging and therapy in other neurodegenerative diseases.
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Introduction
Neurodegenerative diseases are difficult to treat, in part because
of the blood-brain barrier (BBB), a composite of highly specialized
endothelial and perivascular structures that limit transport of
molecules into the brain. Medicinal chemists must extensively
modify drugs in order to bypass the BBB, at significant cost and
delayed time to clinic. Many large biological molecules, such as
antibodies and siRNA, cannot be easily modified to cross the BBB
passively. Although several promising strategies have been
developed for harnessing endogenous active transport systems
[1,2], these techniques have limited carrying capacity and must be
tailor-made for the application. A generic, non-invasive technique
to deliver drugs to the brain would allow preclinical efficacy
screening and facilitate basic research with biological agents.
We and others have shown that low-intensity, focused
ultrasound (FUS) administered with microbubbles (MB) (here
termed FUS-MB therapy), can transiently disrupt the blood-brain
barrier [3,4]. At frequencies suitable for non-invasive trans-skull
focusing [5], FUS-MB causes BBB-disruption only in the
transducer focal volume, which can be selected in real-time by
magnetic resonance (MR) imaging for precise anatomical delivery.
FUS-MB has been used to deliver antibodies, including Herceptin
[6,7] and small-molecule chemotherapeutics [8], in wild-type
animals. To date, FUS-MB has not been applied to neurodegen-
erative disorders, a broad class of diseases that is largely refractory
to current diagnostic and therapeutic approaches.
Alzheimer’s disease (AD) is a progressive and fatal neurodegen-
erative disorder that afflicts millions worldwide and has no cure.
AD pathogenesis is putatively tied to the accumulation of
misfolded proteins, beta-amyloid (Ab) and hyperphosphorylated
tau, which aggregate and form amyloid plaques and tau tangles
[9]. Emerging diagnostic and therapeutic strategies focus on
detecting and reducing Ab aggregates [10,11]. One promising
strategy for amyloid plaque clearance is immunization against Ab,
either by active vaccination with Ab or by administration of anti-
Ab antibodies, termed passive immunization [12]. Screening anti-
Ab antibodies in transgenic AD mouse models generally requires
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due to the cost of purified antibody and transgenic mouse strains.
We believe that FUS-MB might alleviate some of this cost by
allowing localized delivery of anti-Ab antibodies at high
concentration.
In undertaking this study, we were concerned that differences
between aged transgenics and wild-type mice might affect FUS-
MB. For example, aged transgenic mice (often .1 year old)
generally have thicker, more brittle skulls and altered vascular
physiology. Additionally, we wanted to use a simple benchtop
sonication system to allow high throughput FUS-MB for drug
studies. Here we demonstrate that FUS-MB enhances both small-
molecule and antibody delivery in transgenic AD mice and can be
achieved without MRI guidance in a simple benchtop setup.
Results
MRI-Guided Focused Ultrasound-Microbubble Treatment
We initially attempted small-molecule delivery using a proven
MRI-guided sonication protocol [7]. For a targeted imaging
probe, we chose Trypan blue, a bis-azo red fluorescent dye that
shares structural similarity with Congo red (Figure S1) and also
binds amyloid [13]. Normally, Trypan blue does not cross the
BBB because of its size (MW, 916 Da) and hydrophilicity (4
sulfonic acid groups). When the BBB is disrupted, Trypan blue
extravasates into tissue, resulting in a grossly visible blue stain [14],
and thus has been used classically to demonstrate BBB breakdown.
Aged (11–12 month-old), double transgenic mice (n=2)
expressing APPswe and PSEN1dE9 mutations were treated with
MRI-guided FUS-MB (Figure 1), and then received Trypan blue.
BBB-disruption was confirmed in vivo with gadolinium-based,
contrast-enhanced MRI (Figure 2). The millimeter-scale anatom-
ical structures selected pre-treatment were correctly targeted and
exhibited BBB-disruption on T1-weighted fast spin-echo (FSE)
MR images. Gadolinium-based contrast-enhancement was ob-
served in a ,2m m 65 mm ellipsoid confined to the right
hemisphere and traversing the brain from cortex to thalamus,
apparent in the coronal plane (Figure 2). We observed some
contrast in the right ventricle, immediately adjacent to the
intended target position (blue ‘‘+’’, Figure 2A–B).
Post-mortem brains exhibited a distinct blue spot, confined to a
sub-region approximating the dimensions of the transducer focus,
from Trypan blue extravasation across the BBB. No blue staining
was grossly observed in the contralateral hemisphere. On 50-mm
coronal sections, Trypan blue fluorescence was significantly higher
in the treated volume (p=0.02, paired t-test, comparing treated
and untreated regions of interest (ROIs), n=5 animals including 3
from benchtop experiments below) and appeared to concentrate at
small plaque-like inclusions in the cortex, hippocampus, and to a
lesser extent, in the thalamus (Figure 2E).
We confirmed that the Trypan blue-stained aggregates were
amyloid plaques with immunohistochemistry (IHC) using a FITC-
conjugated anti-Ab antibody (3d6) (Figure 2F). In the sonicated
volume, Trypan blue (red) co-localized with FITC-3d6 signal
(green) and stained dense core plaques. When normalized for
background autofluorescence, average Trypan blue fluorescence
was up to 21-fold higher (16.565.4, including benchtop
experiments from below) in the treated vs. untreated cortex.
These results indicate that FUS-MB significantly increased Trypan
blue delivery within the sonication volume and that Trypan blue
Figure 1. Schematic of focused ultrasound system. Mice were
placed supine on the animal platform with the head circled by a
transmit/receive surface MRI coil (constructed in-house); ultrasound was
coupled to the brain from the tank via a water bag. The transducer was
positioned with an xyz positioning system and driven with a PC-
triggered, RF-amplified, function generator.
doi:10.1371/journal.pone.0002175.g001
Figure 2. MRI-guided focused ultrasound-microbubble treat-
ment. Transgenic mice were sonicated at a single location determined
from pre-treatment MR imaging and received intravenous MR-contrast
agent and Trypan blue, an Ab-targeting red fluorophore, after
sonication. (A–B) T1-weighted, contrast-enhanced MR images taken
5 minutes following FUS treatment. Intended sonication locations are
indicated by blue ‘‘+’’. Enhancing volume noted with red. (C–D) Post-
mortem brain; the sonication location is visible as a blue spot in right
hemisphere on photography (C) and red fluorescence (D) from Trypan
blue staining. (E) Trypan blue-labeled amyloid plaques appear as
punctate red fluorescence staining throughout the sonication location.
Inset: black line indicates approximate location of section from whole
brain. In (F–H), multiphoton images of 20 mm sections were stained
with FITC-conjugated anti-Ab antibodies (3d6) to confirm Trypan blue
staining. Green is FITC-3d6, red is Trypan blue. (G) 10x magnified view
of untreated hippocampus. (H) Corresponding treated hippocampus
from the same section. Scale bars: B, 1 cm, F, 1 mm, H, 200 mm.
doi:10.1371/journal.pone.0002175.g002
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target, amyloid plaques.
Aged PDAPP Mice
To test the robustness of FUS-MB across transgenic strains, we
repeated the treatment described above in 26 month-old PDAPP
mice (n=2), which express a mutant form of APP that results in
severe amyloidosis and accompanying pathology, including
neuritic dystrophies, astrocytosis, and microgliosis [15]. We
observed BBB disruption on contrast-enhanced, T1-weighted
FSE imaging following FUS-MB and from Trypan blue staining
in the sonicated hemisphere of post-mortem brains (Figure S2).
Thus, FUS-MB was effective in two different transgenic AD
models, even in extensively aged mice.
Benchtop Focused Ultrasound-Microbubble Therapy
We next tested the capabilities of a MRI-free, benchtop system
by administering Trypan blue or Evans blue, a Trypan blue
isoform (Figure S1), to transgenic mice (n=6, 1 sham-treated)
10 minutes following FUS-MB therapy. The entire procedure
took approximately 5 minutes per animal, compared to 30–
45 minutes with the MR-guided procedure. All treated mice had
distinct blue staining in a focal region of the right hemisphere on
post-mortem examination. We did not observe blue staining in the
sham-treated animal. Sonication locations, determined from blue
staining, were within 2.2 mm of the intended location and
accuracy depended upon the system operator (Figure S3). These
results confirmed that FUS-MB is possible in transgenic animals
using our simple benchtop sonication system, albeit with poorer
localization accuracy.
Focused Ultrasound-Microbubble Enhanced Antibody
Delivery
Although small molecule delivery has some application in AD
therapy and diagnostics, we were primarily interested in the
delivery of much larger biological molecules, such as antibodies,
for AD therapy. Two previous results suggested that antibody
delivery should be possible in aged transgenic mice. First,
experiments by Kinoshita et al demonstrated antibody delivery
to young, wild-type mice using FUS-MB [7]. Furthermore, in our
first FUS-MB experiments in transgenic AD mice, we saw
evidence of endogenous mouse IgG extravasation. When we
stained the FUS-MB treated brains with Alexa 488-conjugated
goat anti-mouse IgG antibodies (Invitrogen, Eugene, OR, USA),
we observed diffuse fluorescence throughout the sonicated volume,
10 to 20-fold greater than in the untreated hemisphere, indicative
of endogenous mouse IgG that had extravasated across the BBB
(Figure 3A).
We next attempted the delivery of Ab-targeted antibodies by
administering rabbit anti-Ab antibodies (Anti-b-Amyloid (1–40)
developed in rabbit, whole antiserum, A 8326, Sigma Aldrich, St.
Louis, Missouri) to transgenic AD mice immediately before
benchtop FUS-MB. Following perfusion and tissue sectioning,
we stained for the rabbit antibody using Alexa Fluor 350
conjugated goat anti-rabbit IgG antibodies (Invitrogen, Eugene,
OR, USA). We observed stronger Alexa Fluor 350 fluorescence
(blue) in the treated hemisphere (p=0.06, paired t-test, n=3,
comparing treated and untreated ROIs normalized to control
tissue) which coincided with Trypan blue-stained amyloid plaques
(see Figure 4).
Alexa Fluor 350 fluorescence did not perfectly match Trypan
blue fluorescence and was somewhat heterogeneous throughout
the sonicated volume, with stronger fluorescence in the hippo-
campus and around a few large blood vessels (Figure 4A). In these
sub-regions, there was strong background staining, which we
interpreted as extravasated, non-specific rabbit IgG, which is the
primary constituent of the whole antiserum preparation. On the
microscopic level, Alexa Fluor 350 fluorescence colocalized with
Trypan blue-positive plaques and vascular amyloid (Figure 4D–F).
Histological Evaluation
We used hemotoxylin and eosin (H&E) stained tissue sections to
assess FUS-MB induced tissue damage in post-mortem brain
sections. 3 of 9 brains had 2–10 scattered petechiae on individual
50-mm H&E sections (Figure 5); 1 of these had petechiae on the
inferior aspect of the brain and in the thalamus, along the axis of
the transducer. When we compared histological effects with the
peak negative pressure applied, we found that the 2 animals
treated at high pressure (estimated 0.8 MPa) had petechiae,
whereas only 1 of 7 treated at a lower pressure (estimated
0.67 MPa) had petechiae. These results were consistent with other
histological studies of FUS-MB damage in rabbit and mice at
similar ultrasound parameters [6,7,16].
Discussion
These experiments demonstrated that ultrasound can enhance
the delivery of small fluorescent agents and large biological
immunotherapeutics in transgenic mouse models of Alzheimer’s
disease. Depending on the strain used, transgenic AD mice are
Figure 3. Endogenous mouse IgG extravasation in ultrasound-treated AD transgenic mouse. 50 mm sections from the ultrasound-treated
mice described in Figure 2 were stained with Alex 488 conjugated goat anti-mouse IgG antibodies and imaged with a microarray plate scanner. (A)
Coronal section through the sonicated volume exhibits Trypan blue (red) and mouse IgG (green) staining. (B) Comparison of average IgG (green) and
Trypan blue (red) in treated (bright) and untreated (dark) cortex, normalized to background fluorescence (Fo) in the untreated thalamus. Regions of
interest are shown in white in (A). Error bars show the standard deviation for the selected regions of interest. Scale bar: A, 1 mm.
doi:10.1371/journal.pone.0002175.g003
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neurological features of AD. The young, wild-type mouse skull
attenuates the acoustic pressure by 1367% [6], whereas the
transgenic AD mouse skull, considerably thicker and more brittle,
could potentially attenuate the ultrasound field even further and
might shift the focal coordinate position. Despite these differences
between transgenic and wild-type animals, we observed robust
Trypan blue delivery in two different transgenic strains for a wide
range of ages (9–26 months). This suggests that, at least at the low
frequency used here (f=0.69 MHz), impedance effects from the
skull could be overcome.
Additionally, some AD transgenic strains have altered vascular
physiology, including increased BBB permeability and risk of
hemorrhage and other vascular accidents [17,18,19,20]. Although
there was some evidence for low Trypan blue leakage in the
untreated hemisphere, FUS-MB increased Trypan blue fluores-
cence 16.5-fold in the treated region (Figure 3B). Furthermore, we
did not see increased histological tissue damage in transgenic mice
compared to previous studies with wild-type mice and rabbits.
Only 1 of 7 mice in this study treated at the lowest pressure
amplitude (0.67 MPa) exhibited petechiae. Thus, FUS-MB
delivery of small molecules can be achieved with minimal
histological damage and markedly increases brain dosage
compared to background BBB ‘‘leak’’ in transgenic AD mouse
models.
Similar dosage enhancement was seen for antibodies (Figure 3B).
We measured a 10–20 fold fluorescence increase for endogenous
IgG in the treated compared to untreated regions and a ,3-fold
fluorescence increase for rabbit anti-Ab IgG. These estimates were
made by comparing average fluorescence from treated and
untreated regions of interest on stained brain sections, with
normalization to background, untreated tissue, and are therefore
only semi-quantitative estimates of relative dose. It is unclear why
endogenous IgG leakage was greater than IV-administered
antibodies. Because IV-administered antibodies were at a
significantly lower concentration than endogenous IgG, it is likely
that this discrepancy represents the limited sensitivity of IHC
staining techniques, as well as tissue fixation, fluorescence
quenching, imaging parameters, and image analysis. However,
we cannot rule out inherently different pharmacokinetics of rabbit
vs. mouse IgG in a mouse model.
Rabbit anti-Ab delivery had a heterogeneous distribution within
the transducer focus, with enhanced Alexa Fluor 350 staining
around large blood vessels and in the hippocampus. This
Figure 4. Ultrasound enhanced delivery of anti-Ab antibodies
in a transgenic AD mouse. Alexa Fluor 350 conjugated goat anti-
rabbit antibodies (blue fluorescence) were used to detect rabbit anti-Ab
antibodies injected immediately before FUS-MB. (A) The brain shows
focal staining in the sonication location that overlaps with Trypan blue-
positive plaques (red fluorescence). Alexa Fluor 350 signal is signif-
icantly stronger in the treated (C) versus untreated (B) hippocampi.
Many plaques show clustered Alexa 350 staining (E) that overlapped
with Trypan blue staining (D) (overlay in F). Scale bars: A, 1 mm, C,
100 mm, F, 100 mm.
doi:10.1371/journal.pone.0002175.g004
Figure 5. Histological evaluation of FUS-MB treatment. Hemotoxylin and eosin stained tissue sections from the treated volume were
examined for signs of tissue damage. We observed scattered petechial hemorrhages in treated regions (A), compared to no damage in untreated
regions (B). (A) Treated hippocampus. Arrowheads indicate petechiae. Inset shows a magnified view of the petechiae on left. (B) Untreated
hippocampus. Scale bars: A-inset, 50 mm, B, 500 mm.
doi:10.1371/journal.pone.0002175.g005
Ultrasound and Alzheimer’s
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Kinoshita et al [7], and might be explained by the limited diffusion
of antibodies within the neuropil or the mechanisms of FUS-MB
mediated BBB disruption. Electron microscopy studies of FUS-
MB enhanced delivery suggest that, following FUS-MB, large
molecules cross the BBB via para-endothelial passages (through
breached tight junctions) or by trans-endothelial, vesicular
transport [21]. These two separate mechanisms were further
corroborated by real-time multiphoton imaging that demonstrated
kinetically distinct delivery processes [22]. Vesicular transport is
preferentially upregulated in arterioles [23], and thus might be
heterogeneously activated across brain anatomy depending on the
relative density of arterioles. Further work is needed to determine
if adequate homogeneity can be achieved for therapeutic efficacy
of anti-Ab antibodies.
Others have suggested that the targeting capabilities of FUS-
MB could be applied for drug delivery to small anatomical targets,
such as the hippocampus [24]. We successfully targeted amyloid
plaques within hippocampus using MRI-guidance, but had some
‘‘off-target’’ delivery in the cortex and thalamus due to the
dimensions of our transducer focal volume (,2m m 614 mm,
ellipsoid). This limitation could be resolved by using a larger
diameter transducer with a tighter focal volume.
Targeting with our benchtop system was less accurate. From the
cohort described here, targeting was within 2.2 mm of the
intended location and varied with the system user (see Figure
S3). Variability was likely due largely to animal motion and
inaccurate animal positioning. Others have used a more
traditional stereo-tactic approach, with the head fixed in ear-bars,
and sonication from an applicator [24,25], with better accuracy.
Because benchtop FUS-MB can be performed with a simple
setup in a short procedure (5 min), it offers the possibility for high-
throughput anti-Ab antibody screening. It is unclear from these
experiments if a single FUS-MB enhanced anti-Ab antibody dose
is adequate for amyloid clearance. Future work will quantify
antibody dose and amyloid clearance in treated animals.
Besides antibodies, FUS-MB may be used to deliver a variety of
imaging and therapeutic molecules to the transgenic mouse brain,
including newly developed amyloid-targeted MR probes [26,27]
and siRNA [28,29]. We believe that FUS-MB may be used for
imaging and drug delivery in transgenic models of neurodegener-
ative diseases besides Alzheimer’s, and could be used for delivering
functional imaging probes to the brain for basic research.
Despite promising advances in immunotherapeutics
[17,30,31,32,33] and PET imaging [34,35,36], Alzheimer’s disease
remains intractable to current therapeutic and diagnostic strategies.
By overcoming the BBB, FUS-MB may potentiate agents with
demonstrated efficacy and could open new avenues of research by
reducing the developmental constraints on new Alzheimer’s agents.
We view this as a powerful preclinical research tool.
A clinical FUS system composed of a 512-element phased
transducer array at a frequency similar to the current study
(670 kHz) has been developed for MRI-guided intracranial
thermal ablation [5,37]. We suggest that such a system could
feasibly be used at low powers to achieve noninvasive BBB
disruption with high spatial resolution for targeted FUS-MB
delivery. Before translation to the humans, however, FUS-MB
must pass vigorous safety and efficacy benchmarks to prove
therapeutic benefit and minimize side-effects. Furthermore, we
must better understand the underlying biomechanical mechanisms
for FUS-MB therapy. Ongoing work at our institutions is aimed at
understanding the cellular response to FUS-MB and demonstrat-
ing the therapeutic effects of FUS-MB-enhanced drug delivery for
CNS disorders.
Materials and Methods
MR-guided FUS-MB Treatment
All animal experiments were performed at Brigham and
Women’s Hospital under national and institutional guidelines
using protocols authorized by the Harvard Medical Area Standing
Committee on Animals. Experiments were conducted using an
MR-compatible sonication system consisting of an ultrasound
transducer submerged in a small tank of degassed, deionized water
coupled to an animal platform above (see Figure 1). The
transducer was attached to a manual XYZ positioning system to
allow fine positioning of the focal volume. Sonication pressure and
power were estimated from calibration measurements described
previously [6]. The entire sonication system was placed on the MR
table and moved into a clinical 3T MR scanner (GE Healthcare,
Milwaukee, WI) for imaging. We determined focal volume
coordinates by MR thermometry in a gel phantom sonicated at
high powers [38].
Transgenic mice (n=2, 11–12 month old, B6C3-Tg(APPswe,
PSEN1dE9)85Dbo/J; n=2, 26 month old, PDAPP) were
anesthetized (70 mg/kg ketamine, 10 mg/kg xylazine) and
prepped for treatment by shaving and depilating the head with
depilatory lotion. Mice were placed supine on the animal platform
and imaged pre-treatment to specify the sonication location
coordinates; the transducer focus was then moved using the
manual positioner. Mice were sonicated (f=0.69 MHz, burst
length=10 ms, pulse repetition frequency=1 Hz, peak negative
pressure=0.67–0.8 MPa, estimated acoustic power=0.28–0.4 W,
exposure length=40–45 s) with concomitant IV administration of
a microbubble contrast agent (0.03–0.05 ml Optison, GE
Healthcare, Chalfont, St Giles, UK, or 0.01 ml 1:10 diluted
Definity in saline, Bristol-Myers Squibb, New York, NY) and
subsequent BBB-disruption was monitored with T1-weighted fast
spin echo MRI following IV administration of gadopentetate
dimeglumine (Magnevist, Berlex Laboratories, Inc., Wayne, NJ)
administered IV (0.25 ml/4 kg) as a bolus injection. Mice received
Trypan blue (0.06 ml, 4%, IV) 10 minutes following FUS-MB.
We perfused the mice 3–4 hrs after FUS-MB (5 ml saline and 5 ml
10% phosphate-buffered formalin), and extracted the brains for
post-mortem analysis.
Benchtop FUS-MB Treatment
Similar to above, the transducer was mounted on an XYZ
positioning system and submerged in a tank of degassed, deionized
water. Ultrasound energy was coupled to the animal above via a
mylar window. Before experiments, the transducer was focused
onto cross-hairs drawn onto the mylar window, providing a
reference for animal alignment. Mice were placed supine with the
shaved head directly contacting a mylar window and positioned
such that the transducer focus was 4 mm caudal to the eyes and
centrally aligned; the transducer was then moved 2–3 mm to the
right to place the transducer focus squarely in the right
hemisphere.
Transgenic mice (n=8, 9–12 month old, B6C3-Tg(APPswe,
PSEN1dE9)85Dbo/J) were anesthetized and prepped for treat-
ment as described above. Of the 8 mice, 5 were treated and
included in study, 1 was sham-treated, and 2 were excluded
because they died before or during treatment, putatively from
anesthesia. We treated the mice as described above with
ultrasound exposure and concurrent IV administration of micro-
bubbles. Some mice (n=3) received rabbit anti-Ab antibodies
(0.1 ml of 53 mg/ml whole sera, Sigma Aldrich) IV immediately
before FUS-MB. Ten minutes following FUS-MB, mice received
Trypan blue or Evans blue (0.06 ml, 4%, IV), which are used
Ultrasound and Alzheimer’s
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after FUS-MB as above.
Tissue Analysis
Extracted brains were photographed (FinePix S7000, Fuji-film,
Japan) and imaged using a multi-spectral small animal imaging
system (Maestro, CRI, Woburn, MA, USA) to confirm Trypan
blue staining. Brains were sectioned at 20 or 50 mm and
representative sections were stained using standard IHC or
H&E. Prepared sections were mounted and imaged using
multiphoton microscopy (Bio-Rad Laboratories,
Hercules, CA, USA) and a microarray scanner (ScanArray
Express, Perkin Elmer, Waltham, MA, USA). Images were
analyzed using ImageJ [39]. Fluorescence fold changes were
calculated by comparing the mean fluorescence in large ROIs
from treated and contralateral untreated cortex. Fluorescence
counts were normalized to mean signal from untreated thalamus
to reduce the artifact from background staining and autofluores-
cence (so-called Fo in Figure 3).
Supporting Information
Figure S1 Chemical structures of amyloid imaging fluorophores.
(A) Congo red, (B) Trypan blue, and (C) Evans blue.
Found at: doi:10.1371/journal.pone.0002175.s001 (0.41 MB TIF)
Figure S2 MRI-guided focused ultrasound-microbubble treat-
ment in PDAPP mice. Aged PDAPP mice were treated with FUS-
MB at a location determined from pre-treatment MR imaging and
received intravenous MR-contrast agent and Trypan blue, an Ab-
targeting red fluorophore, after sonication. (A–B) T1-weighted,
contrast-enhanced MR images taken 5 minutes following FUS
treatment. Intended sonication locations are indicated by blue ‘‘+’’.
(C–D) Post-mortem brain; the sonication location is faintly visible as
a blue spot in right hemisphere on photography (C) and red
fluorescence (D) from Trypan blue staining. Scale bar: B, 1 cm.
Found at: doi:10.1371/journal.pone.0002175.s002 (5.40 MB TIF)
Figure S3 Benchtop focused ultrasound-microbubble treatment.
Transgenic mice were sonicated at a single location in the right
hemisphere using a benchtop sonication system and received
Trypan blue or Evans blue IV. 5/5 animals exhibited focal blue
staining in the right hemisphere. (a) Focal blue staining from
Trypan blue on post-mortem, excised brain. (b) Schematic
displaying sonication locations (red and blue dotted lines) from
two different system users (red vs. blue) for two intended target
locations (red and blue crosses). Scale bar: B, 1 cm.
Found at: doi:10.1371/journal.pone.0002175.s003 (5.14 MB TIF)
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